Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. reports developments around cell engineering, autonomous laboratory infrastructure, and contract research services that make biological R&D more programmable. Its updates cover Ginkgo Cloud Lab, Datapoints and Solutions services, Reconfigurable Automation Carts, Catalyst automation software, and AI-enabled workflows for protein engineering, nucleic acid design, cell-free systems, and biological manufacturing.
Company news also includes financial-results presentations, customer and research collaborations, agricultural biotechnology manufacturing work, and capital or governance updates. Following the completed divestiture of its Biosecurity business, recurring coverage centers on Ginkgo's autonomous lab strategy, remote wet-lab access, microbial strain engineering, fermentation processes, and the commercial use of lab-generated biological data.
Summary not available.
Cronos Group (NASDAQ: CRON) and Ginkgo Bioworks (NYSE: DNA) have achieved a productivity milestone in their collaboration to produce cultured cannabinoids, specifically tetrahydrocannabivarin (THCV). This development is part of an initiative launched in 2018 aimed at creating rare cannabinoids at industrial scale. Cronos has issued approximately 2.2 million common shares to Ginkgo as a result of this achievement. The partnership underscores both companies' commitment to innovation in the cannabis industry, enhancing Cronos' product pipeline with potential market introductions for THCV.
Ginkgo Bioworks (NYSE: DNA) will participate in Goldman Sachs' 43rd Annual Global Healthcare Conference on June 15, 2022, at 10:40 a.m. PT. The company focuses on cell programming, providing a platform for biotechnology applications across various sectors including pharmaceuticals and agriculture. Ginkgo has also supported COVID-19 efforts such as pooled testing and vaccine optimization. Further details, including a webcast link, will be available on their investor relations website.
On June 7, 2022, Ginkgo Bioworks (NYSE: DNA) announced a collaboration with Novo Nordisk to develop novel expression hosts for pharmaceutical products targeting chronic diseases like diabetes and obesity. This partnership aims to enhance the discovery and development of biological medicines. Ginkgo will receive an upfront R&D fee and may earn milestone payments throughout the collaboration. This multi-year project underscores Ginkgo's commitment to leveraging synthetic biology for improved healthcare solutions.
On June 6, 2022, Ginkgo Bioworks (NYSE: DNA) announced the acquisition of assets from Bitome, a leader in real-time metabolite monitoring technology. This technology uses machine learning to enhance bioprocess optimization by providing continuous monitoring of cell culture media. The integration aims to streamline the development timelines of Ginkgo's cell programming platform, potentially accelerating product readiness. Ginkgo's co-founder highlighted that this acquisition will significantly improve strain testing at scale, addressing a critical bottleneck in synthetic biology.
Ginkgo Bioworks (NYSE: DNA) will participate in William Blair's 42nd Annual Growth Stock Conference on June 9, 2022, at 11:20 a.m. CT. The conference aims to showcase growth stocks to investors and provide insights into Ginkgo's cell programming platform, which serves various markets from agriculture to pharmaceuticals. Details about the event, including a webcast link and a replay, can be found on the company's investor relations website.
Ginkgo Bioworks (NYSE: DNA) and First Serv have announced a non-binding MOU to develop biosecurity capabilities in Qatar, aiming to establish a global pathogen monitoring network. This partnership leverages Ginkgo's biosecurity platform and Qatar's investments in biotechnology to enhance pathogen detection and response capabilities. The initiative is intended to position Doha as a critical node for global pathogen monitoring, facilitating informed public health decisions amid potential biological threats. This collaboration marks Ginkgo's strategic international expansion in biosecurity.
Ginkgo Bioworks reported Q1 2022 revenue of $168 million, up 282% YoY, primarily driven by its biosecurity business, which generated $147 million. The company added 11 new Cell Programs, reflecting 175% growth. Full-year revenue guidance has increased from $325-$340 million to $375-$390 million. Ginkgo maintains a $1.5 billion cash balance, supporting future growth initiatives. However, it experienced a significant loss of $(675 million) in operations due to stock-based compensation. The company anticipates adding 60 new Cell Programs in 2022.
Evo Foods and Ginkgo Bioworks have announced a partnership aimed at developing animal-free egg proteins to enhance Evo's product line. This initiative comes in response to increasing consumer demand for sustainable food alternatives. Evo, founded in 2020, aims to end animal agriculture by creating superior substitutes for animal products, starting with eggs. Utilizing Ginkgo's advanced Cell Development Kits, Evo seeks to innovate and improve the culinary properties of egg substitutes. Both companies emphasize their commitment to sustainability and meeting market needs.
Ginkgo Bioworks (NYSE: DNA) will host a presentation and Q&A session on May 16, 2022, at 4:30 p.m. ET, to review its first-quarter performance ending March 31, 2022. The session will be accessible via Ginkgo's investor relations website, where a replay will also be available. This meeting aims to provide investors with insights into Ginkgo's business metrics and future projections, reinforcing its position in the biotechnology sector with applications in various markets including food, agriculture, and pharmaceuticals.